Betting on immunotherapy for melanoma

Current Oncology Reports

Volumn 11, Issue 5, 2009, Pages 397-404

  Sznol, Mario ^a  

^a YALE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; CD40 LIGAND MONOCLONAL ANTIBODY; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; DACARBAZINE; INTERLEUKIN 15; INTERLEUKIN 2; INTERLEUKIN 21; IPILIMUMAB; PROTEIN PD 1 ANTIBODY; T LYMPHOCYTE RECEPTOR; TICILIMUMAB; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTHROPATHY; CANCER IMMUNIZATION; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL SPECIFICITY; CELL VIABILITY; CLINICAL TRIAL; COLITIS; CROSS REACTION; CYTOKINE RELEASE SYNDROME; CYTOTOXIC T LYMPHOCYTE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HUMAN; IMMUNOSTIMULATION; IMMUNOTHERAPY; LIVER FUNCTION TEST; LYMPHOCYTE ACTIVATION; LYMPHOCYTE FUNCTION; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVERALL SURVIVAL; REGULATORY T LYMPHOCYTE; REVIEW; SIDE EFFECT; THROMBOCYTOPENIA;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD; HUMANS; IMMUNOTHERAPY; MELANOMA; TREATMENT OUTCOME;

EID: 68949156442     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-009-0053-z     Document Type: Review

References (50)

1. Tsao H, Atkins MB, Sober AJ: Management of cutaneous melanoma. N Engl J Med 2004, 351:998-1012.
2. Korn EL, Liu PY, Lee SJ, et al.: Meta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trials. J Clin Oncol 2008, 26:527-534.
3. Atkins MB, Lotze MT, Dutcher JP, et al.: High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: Analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999, 17:2105-2116.
4. Kirkwood JM, Manola J, Ibrahim J, et al.: A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004, 10:1670-1677.
5. Atkins MB: Cytokine-based therapy and biochemotherapy for advanced melanoma. Clin Cancer Res 2006, 12:2353s-2358s.
6. Smith FO, Downey SG, Klapper JA, et al.: Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res 2008, 14:5610-5618.
7. Yu H, Kortylewski M, Pardoll D: Crosstalk between cancer and immune cells: Role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7: 41-51.
8. Drake CG, Jaffee E, Pardoll DM: Mechanisms of immune evasion by tumors. Adv Immunol 2006, 90:51-81.
9. Gajewski TF, Meng Y, Blank C, et al.: Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006, 213:131-145.
10. Demotte N, Stroobant V, Courtoy PJ, et al.: Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 2008, 28:414-424.
11. Katz JB, Muller AJ, Prendergast GC: Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape. Immunol Rev 2008, 222:206-221.
12. Buckanovich RJ, Facciabene A, Kim S, et al.: Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy. Nat Med 2008, 14:28-36.
13. Marigo I, Dolcetti L, Serafini P, et al.: Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
14. Groh V, Wu J, Yee C, Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002, 419:734-738.
15. Solana R, Casado JG, Delgado E, et al.: Lymphocyte activation in response to melanoma: Interaction of NK-associated receptors and their ligands. Cancer Immunol Immunother 2007, 56:101-109.
16. Lin KY, Lu D, Hung CF, et al.: Ectopic expression of vascular cell adhesion molecule-1 as a new mechanism for tumor immune evasion. Cancer Res 2007, 67:1832-1841.
17. Steinman RM: DendriAic cells in vivo: a key target for a new vaccine science. Immunity 2008, 29:319-324.
18. Melero I, Hervas-Stubbs S, Glennie M, et al.: Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer 2007, 7:95-106.
19. Dudley ME, Yang JC, Sherry R, et al.: Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 2008, 26:5233-5239.
20. Rosenberg SA, Yannelli JR, Yang JC, et al.: Treatment of patients with metastatic melanoma with autologous tumorinfiltrating lymphocytes and interleukin 2. J Natl Cancer Inst 1994, 86:1159-1166.
21. Weber C: Ipilimumab: controversies in its development, utility, and autoimmune adverse events. Cancer Immunol Immunother 2009, 58:823-830.
22. Ribas A: Overcoming immunologic tolerancT to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206). Oncologist 2008, 13(Suppl 4):10-15.
23. Downey SG, Klapper JA, Smith FO, et al.: Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clin Cancer Res 2007, 13:6681-6688.
24. Dudley ME, Wunderlich JR, Shelton TE, et al.: Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother 2003, 26:332-342.
25. Lee PP, Yee C, Savage PA, et al.: Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med 1999, 5:677-685.
26. Preuss KD, Zwick C, Bormann C, et al.: Analysis of the B-cell repertoire against antigens expressed by human neoplasms. Immunol Rev 2002, 188: 43-50.
27. Fife BT, Bluestone JA: Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol Rev 2008, 224:166-182.
28. Dong H, Strome SE, Salomao DR, et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
29. Sadlack B, Lohler J, Schorle H, et al.: Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995, 25:3053-3059.
30. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell 2008, 133:775-787.
31. Antony PA, Paulos CM, Ahmadzadeh M, et al.: Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol 2006, 176:5255-5266.
32. Teague RM, Sather BD, Sacks JA, et al.: Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat Med 2006, 12:335-341.
33. Zeng R, Spolski R, Finkelstein SE, et al.: Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005, 201:139-148.
34. Wan YY, Flavell RA: TGF-beta and regulatory T cell in immunity and autoimmunity. J Clin Immunol 2008, 28:647-659.
35. Rosenberg SA, RestAfo NP, Yang JC, et al.: Adoptive cell transfer: a clinical path to effective cancer immunotherapy. Nat Rev Cancer 2008, 8:299-308.
36. Muranski P, Boni A, Antony PA, et al.: Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood 2008, 112:362-373.
37. Morgan RA, Dudley ME, Wunderlich JR, et al.: Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 2006, 314:126-129.
38. Stephan MT, Ponomarev V, Brentjens RJ, et al.: T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med 2007, 13:1440-1449.
39. Rosenberg SA, YaMg JC, Restifo RP: Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004, 10:909-915.
40. Bonifaz LC, Bonnyay DP, Charalambous A, et al.: In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 2004, 199:815-824.
41. Dubsky P, Saito H, Leogier M, et al.: IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T cells to differentiate into CTL. Eur J Immunol 2007, 37: 1678-1690.
42. Ahonen CL, Wasiuk A, Fuse S, et al.: Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood 2008, 111:3116-3125.
43. van Elsas A, Sutmuller RP, Hurwitz AA, et al.: Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: Comparison of prophylaxis and therapy. J Exp Med 2001, 194:481-489.
44. Wing K, Onishi Y, Prieto-Martin P, et al.: CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
45. Hegel JK, Knieke K, Kolar P, et al.: CD152 (CTLA-4) regulates effector functions of CD8+ T lymphocytes by repressing Eomesodermin. Eur J Immunol 2009, 39:883-893.
46. Ribas A, Hauschild A, Kefford R, et al.: Phase III, openlabel, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide or dacarbazine) in patients with advanced melanoma [abstract]. J Clin Oncol 2008, 26: LBA9011.
47. Maker AV, Phan GQ, Attia P, et al.: Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: A phase I/II study. Ann Surg Oncol 2005, 12:1005-1016.
48. Hunder NN, Wallen H, Cao J, et al.: Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008, 358:2698-2703.
49. Brahmer JR, Topalian S, Wollner I, et al.: Safety and activity of MDX-1106 (ONO-4538), an anti-PD1 monoclonal antibody, in patients with selected refractory or relapsed malignancies [abstract]. J Clin Oncol 2008, 26:3006.
50. Vonderheide RH, Flaherty KT, Khalil M, et al.: Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007, 25: 876-883.